Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS)

Next Previous
Trial Profile

An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Sepsis
  • Focus Therapeutic Use
  • Acronyms LeoPARDS

Most Recent Events

  • 10 Nov 2016 According to Tenax Therapeutics media release, in October, company presented initial results at the 29th European Society of Intensive Care Medicine (ESICM) Annual Congress.
  • 01 Nov 2016 Status changed from active, no longer recruiting to completed.
  • 05 Oct 2016 Primary endpoint has not been met, (Mean sequential organ failure assessment (SOFA) score), according to the results published.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top